CN112867708A - 一种mdm2抑制剂,及其制备方法、药物组合物和应用 - Google Patents
一种mdm2抑制剂,及其制备方法、药物组合物和应用 Download PDFInfo
- Publication number
- CN112867708A CN112867708A CN201980064565.7A CN201980064565A CN112867708A CN 112867708 A CN112867708 A CN 112867708A CN 201980064565 A CN201980064565 A CN 201980064565A CN 112867708 A CN112867708 A CN 112867708A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- group
- compound
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
涉及一种MDM2抑制剂、其制备方法、其药物组合物和应用。具体地,涉及一种如式I所示的化合物,所述的化合物具有优异的MDM2抑制活性,可用于制备治疗癌症和其他MDM2活性相关疾病的药物组合物,特别是,p53野生型癌症。
Description
PCT国内申请,说明书已公开。
Claims (10)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018111601630 | 2018-09-30 | ||
CN201811160163.0A CN110963958A (zh) | 2018-09-30 | 2018-09-30 | 一种mdm2抑制剂,及其制备方法、药物组合物和应用 |
PCT/CN2019/109428 WO2020064004A1 (zh) | 2018-09-30 | 2019-09-30 | 一种mdm2抑制剂,及其制备方法、药物组合物和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112867708A true CN112867708A (zh) | 2021-05-28 |
CN112867708B CN112867708B (zh) | 2023-05-12 |
Family
ID=69949744
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811160163.0A Pending CN110963958A (zh) | 2018-09-30 | 2018-09-30 | 一种mdm2抑制剂,及其制备方法、药物组合物和应用 |
CN201980064565.7A Active CN112867708B (zh) | 2018-09-30 | 2019-09-30 | 一种mdm2抑制剂,及其制备方法、药物组合物和应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811160163.0A Pending CN110963958A (zh) | 2018-09-30 | 2018-09-30 | 一种mdm2抑制剂,及其制备方法、药物组合物和应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11299460B2 (zh) |
EP (1) | EP3858812A4 (zh) |
JP (1) | JP7338896B2 (zh) |
KR (1) | KR102610545B1 (zh) |
CN (2) | CN110963958A (zh) |
AU (1) | AU2019351530B2 (zh) |
WO (1) | WO2020064004A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114853731A (zh) * | 2021-02-04 | 2022-08-05 | 上海长森药业有限公司 | 一种双功能mdm2蛋白降解剂,及其制备方法、药物组合物和应用 |
WO2023089375A1 (en) * | 2021-11-22 | 2023-05-25 | Ligature Therapeutics Pte, Ltd. | Therapeutic compounds and methods of use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103180296A (zh) * | 2010-06-04 | 2013-06-26 | 安姆根有限公司 | 用于治疗癌症的作为mdm2抑制剂的哌啶酮衍生物 |
CN105121407A (zh) * | 2013-02-28 | 2015-12-02 | 美国安进公司 | 用于治疗癌症的苯甲酸衍生物mdm2抑制剂 |
CN105358530A (zh) * | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2850166C (en) * | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
ES2916721T3 (es) * | 2013-11-11 | 2022-07-05 | Amgen Inc | Terapia de combinación que incluye un inhibidor de MDM2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres |
JP7037500B2 (ja) * | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Mdm2タンパク質分解剤 |
US10759808B2 (en) * | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
KR102325778B1 (ko) * | 2016-11-15 | 2021-11-12 | 노파르티스 아게 | HDM2-p53 상호작용 억제제에 대한 용량 및 요법 |
-
2018
- 2018-09-30 CN CN201811160163.0A patent/CN110963958A/zh active Pending
-
2019
- 2019-09-30 EP EP19864128.4A patent/EP3858812A4/en active Pending
- 2019-09-30 WO PCT/CN2019/109428 patent/WO2020064004A1/zh unknown
- 2019-09-30 KR KR1020217013158A patent/KR102610545B1/ko active IP Right Grant
- 2019-09-30 AU AU2019351530A patent/AU2019351530B2/en active Active
- 2019-09-30 JP JP2021517766A patent/JP7338896B2/ja active Active
- 2019-09-30 CN CN201980064565.7A patent/CN112867708B/zh active Active
- 2019-09-30 US US17/281,368 patent/US11299460B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103180296A (zh) * | 2010-06-04 | 2013-06-26 | 安姆根有限公司 | 用于治疗癌症的作为mdm2抑制剂的哌啶酮衍生物 |
CN105153014A (zh) * | 2010-06-04 | 2015-12-16 | 安姆根有限公司 | 用于治疗癌症的作为mdm2抑制剂的哌啶酮衍生物 |
CN105121407A (zh) * | 2013-02-28 | 2015-12-02 | 美国安进公司 | 用于治疗癌症的苯甲酸衍生物mdm2抑制剂 |
CN105358530A (zh) * | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
Non-Patent Citations (3)
Title |
---|
ANA Z. GONZALEZ ET AL: ""Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres"", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 57, no. 7, 6 May 2014 (2014-05-06), pages 2963 - 2988, XP055116598, DOI: 10.1021/jm401911v * |
ANA Z. GONZALEZ ET AL: ""Selective and Potent Morpholinone Inhibitors of the MDM2−p53 Protein−Protein Interaction"", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 57, 18 February 2014 (2014-02-18), pages 2472 - 2488 * |
DAQING SUN ET AL: ""Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2−p53 Inhibitor in Clinical Development"", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 57, 23 January 2014 (2014-01-23), pages 1454 - 1472 * |
Also Published As
Publication number | Publication date |
---|---|
CN112867708B (zh) | 2023-05-12 |
AU2019351530B2 (en) | 2022-11-17 |
CN110963958A (zh) | 2020-04-07 |
WO2020064004A1 (zh) | 2020-04-02 |
EP3858812A1 (en) | 2021-08-04 |
JP2022502448A (ja) | 2022-01-11 |
KR102610545B1 (ko) | 2023-12-05 |
JP7338896B2 (ja) | 2023-09-05 |
EP3858812A4 (en) | 2022-07-06 |
US20220002248A1 (en) | 2022-01-06 |
US11299460B2 (en) | 2022-04-12 |
KR20210093870A (ko) | 2021-07-28 |
AU2019351530A1 (en) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113767103B (zh) | 新型螺环类K-Ras G12C抑制剂 | |
CN113286794B (zh) | Kras突变蛋白抑制剂 | |
CN114901661A (zh) | 新型K-Ras G12C抑制剂 | |
CN113544128A (zh) | Kras-g12c抑制剂 | |
WO2021063346A1 (zh) | Kras g12c抑制剂及其应用 | |
CN112341457A (zh) | Kras突变蛋白抑制剂 | |
CN113754653A (zh) | 一种kras g12c抑制剂化合物及其用途 | |
WO2015077193A1 (en) | Inhibitors of lysine methyl transferase | |
EP3638680B1 (en) | Heteroaromatic compounds as vanin inhibitors | |
CN107207504B (zh) | 酞嗪酮衍生物、其制备方法及用途 | |
CN113874015B (zh) | Ripk2的噻吩并吡啶抑制剂 | |
CN112824420B (zh) | 用作egfr激酶抑制剂的化合物及其应用 | |
CN108349947B (zh) | 四氢吲唑及其医药用途 | |
CN116354936A (zh) | 用作选择性aurora a抑制剂的新型杂环化合物 | |
CN114835703A (zh) | 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用 | |
CN113372351A (zh) | 一类jak激酶抑制剂及其制备和应用 | |
CN112867708B (zh) | 一种mdm2抑制剂,及其制备方法、药物组合物和应用 | |
CN112079839A (zh) | 内酰胺类衍生物、其制备方法及其在医药上的用途 | |
CN113045569B (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
CN114621256A (zh) | 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用 | |
CN114853731A (zh) | 一种双功能mdm2蛋白降解剂,及其制备方法、药物组合物和应用 | |
CN115698011A (zh) | Pb2抑制剂及其制备方法和用途 | |
JP7369968B2 (ja) | 抗がん剤 | |
CN114380805A (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
CN115348861A (zh) | α-5 β-1抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40043315 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |